Security
Zentalis Pharmaceuticals, Inc. Common Stock · ZNTL
ZNTLNASDAQCommon stockCurrentCIK 1725160Updated Oct 28, 2026
Name history
Zentalis Pharmaceuticals, LLC · through Apr 6, 2020Zeno Pharma, LLC · through Sep 5, 2019
ZNTL price & chart
Loading TradingView…
NASDAQ:ZNTL on TradingView ↗About the company
Zentalis® Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (PROC). Azenosertib is being evaluated as a monotherapy and in combination across multiple tumor types in clinical trials and has broad franchise potential. In clinical trials, azenosertib has been well tolerated and has demonstrated anti-tumor activity as a single agent across multiple tumor types. The Company is also leveraging its extensive experience and capabilities to translate its science to advance research on additional areas of opportunity for azenosertib outside PROC. Zentalis has operations in San Diego.
In the news
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ↗
Recent filings
4 filing
Other Events
Items 8.01, 9.01
424B5 filing
424B5 filing
10-Q filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 327,250,000Source | 450,661,000Source | 215,330,000Source | 351,707,000Source | 491,680,000Source | 253,066,000Source | 384,021,000Source | 557,479,000Source | 288,967,000Source | 430,337,000Source | 551,688,000Source | 539,310,000Source |
| Property, Plant and Equipment, NetUSD | 2,927,000Source | 5,016,000Source | 2,500,000Source | 3,087,000Source | 5,337,000Source | 2,653,000Source | 3,247,000Source | 5,679,000Source | 2,770,000Source | 4,699,000Source | 5,819,000Source | 7,705,000Source |
| GoodwillUSD | — | 3,736,000Source | — | — | 3,736,000Source | — | — | 3,736,000Source | — | 0Source | 3,736,000Source | 3,736,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 39,072,000Source | 41,320,000Source | 24,783,000Source | 37,599,000Source | 36,976,000Source | 31,930,000Source | 41,929,000Source | 37,616,000Source | 35,995,000Source | 33,901,000Source | 28,038,000Source | 43,069,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 0Source | — | — | 0Source | — | — | 0Source | — | 0Source | 5,000,000Source | — | — |
| Assets, CurrentUSD | 288,302,000Source | 400,270,000Source | 181,279,000Source | 311,596,000Source | 439,616,000Source | 218,096,000Source | 342,882,000Source | 503,806,000Source | 253,191,000Source | 386,066,000Source | 496,718,000Source | 451,933,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 7,605,000Source | 9,018,000Source | 6,671,000Source | 8,165,000Source | 13,231,000Source | 6,338,000Source | 10,429,000Source | 14,822,000Source | 7,298,000Source | 9,982,000Source | 13,799,000Source | 14,562,000Source |
| Operating Lease, Right-of-Use AssetUSD | 30,188,000Source | 33,403,000Source | 24,795,000Source | 31,175,000Source | 33,474,000Source | 25,595,000Source | 31,925,000Source | 34,726,000Source | 26,271,000Source | 32,528,000Source | 35,916,000Source | 42,373,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 74,376,000Source | 96,330,000Source | 71,684,000Source | 77,212,000Source | 109,099,000Source | 70,386,000Source | 88,639,000Source | 98,708,000Source | 72,763,000Source | 93,151,000Source | 114,297,000Source | 105,286,000Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 72,000Source | 71,000Source | 72,000Source | 72,000Source | 71,000Source | 71,000Source | 72,000Source | 70,000Source | 69,000Source | 71,000Source | 70,000Source | 59,000Source |
| Additional Paid in CapitalUSD | 1,408,855,000Source | 1,359,589,000Source | 1,412,745,000Source | 1,403,912,000Source | 1,349,135,000Source | 1,409,466,000Source | 1,397,626,000Source | 1,336,416,000Source | 1,407,394,000Source | 1,390,952,000Source | 1,323,576,000Source | 1,031,462,000Source |
| Retained Earnings (Accumulated Deficit)USD | -1,156,239,000Source | -1,006,923,000Source | -1,269,093,000Source | -1,129,548,000Source | -966,765,000Source | -1,226,807,000Source | -1,102,674,000Source | -878,488,000Source | -1,191,455,000Source | -1,054,395,000Source | -888,556,000Source | -596,365,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 186,000Source | 1,594,000Source | -78,000Source | 59,000Source | 140,000Source | -50,000Source | 358,000Source | 773,000Source | 196,000Source | 558,000Source | 2,194,000Source | -1,353,000Source |
| Stockholders' Equity Attributable to ParentUSD | 252,874,000Source | 354,331,000Source | 143,646,000Source | 274,495,000Source | 382,581,000Source | 182,680,000Source | 295,382,000Source | 458,771,000Source | 216,204,000Source | 337,186,000Source | 437,284,000Source | — |
| Liabilities and EquityUSD | 327,250,000Source | 450,661,000Source | 215,330,000Source | 351,707,000Source | 491,680,000Source | 253,066,000Source | 384,021,000Source | 557,479,000Source | 288,967,000Source | 430,337,000Source | 551,688,000Source | 539,310,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 37,168,000Source | 54,877,000Source | 37,626,000Source | 39,022,000Source | 66,692,000Source | 35,236,000Source | 49,430,000Source | 54,798,000Source | 36,559,000Source | 52,725,000Source | 69,367,000Source | 56,647,000Source |
| Operating Lease, Liability, CurrentUSD | 3,749,000Source | 2,809,000Source | 4,132,000Source | 3,627,000Source | 2,709,000Source | 4,001,000Source | 3,509,000Source | 2,739,000Source | 3,873,000Source | 3,072,000Source | 2,623,000Source | 2,162,000Source |
| Accounts Payable, CurrentUSD | 7,031,000Source | 8,202,000Source | 8,142,000Source | 3,719,000Source | 20,440,000Source | 7,378,000Source | 7,769,000Source | 10,502,000Source | 7,208,000Source | 7,438,000Source | 14,926,000Source | 11,247,000Source |
| Operating Lease, Liability, NoncurrentUSD | 36,708,000Source | 40,457,000Source | 33,558,000Source | 37,690,000Source | 41,318,000Source | 34,650,000Source | 38,651,000Source | 42,616,000Source | 35,704,000Source | 39,577,000Source | 43,150,000Source | 45,166,000Source |
| Deferred Income Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 853,000Source |
| Other Liabilities, NoncurrentUSD | 500,000Source | 996,000Source | 500,000Source | 500,000Source | 1,089,000Source | 500,000Source | 558,000Source | 1,294,000Source | 500,000Source | 849,000Source | 1,780,000Source | 2,620,000Source |
| Stockholders' Equity Attributable to Noncontrolling InterestUSD | — | 0Source | — | — | 0Source | — | — | 0Source | — | 0Source | 107,000Source | — |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 30,137,000Source | 46,675,000Source | 29,484,000Source | 35,303,000Source | 46,252,000Source | 27,858,000Source | 41,661,000Source | 44,296,000Source | 29,351,000Source | 45,287,000Source | 54,441,000Source | 45,400,000Source |
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | — | — | — | 853,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | -26,691,000Source | -40,158,000Source | — | -26,874,000Source | — | -48,279,000Source | -137,060,000Source | -165,867,000Source | -292,305,000Source | -237,113,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | 160,000Source | 321,000Source | 152,000Source | 160,000Source | 151,000Source | 262,000Source | 739,000Source | 1,289,000Source | 1,389,000Source | 1,426,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 3,197,000Source | 6,486,000Source | 20,722,000Source | 67,269,000Source | 54,822,000Source | 46,840,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | — | — | -5,000,000Source | 5,000,000Source | — | — |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 51,000Source | -63,000Source | -891,000Source | -778,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -32,956,000Source | -32,636,000Source | -125,247,000Source | -170,860,000Source | -207,822,000Source | -163,751,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 30,014,000Source | 40,475,000Source | 131,623,000Source | 176,561,000Source | -44,458,000Source | -114,180,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 34,000Source | 0Source | 0Source | 221,000Source | 583,000Source | 2,548,000Source |
| Cash flows from financing activities: | ||||||||||||
| Payments for Repurchase of Common StockUSD | — | — | — | — | — | — | — | — | 9,976,000Source | — | — | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | -1,123,000Source | 189,000Source | -4,282,000Source | 108,000Source | 237,303,000Source | 261,043,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -4,065,000Source | 8,028,000Source | 2,094,000Source | 5,809,000Source | -14,977,000Source | -16,888,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 41,699,000Source | 43,947,000Source | 27,410,000Source | 40,226,000Source | 34,557,000Source | 44,556,000Source | 38,622,000Source | 36,528,000Source | 30,719,000Source | 45,696,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 85,000Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 4,828,000Source | 10,362,000Source | 3,215,000Source | 6,286,000Source | 3,197,000Source | 6,486,000Source | 20,722,000Source | 67,269,000Source | 54,822,000Source | 46,840,000Source |
| AssetAcquisitionContingentConsiderationLiabilityUSD | — | — | 500,000Source | 500,000Source | 500,000Source | 500,000Source | 500,000Source | 500,000Source | 500,000Source | 500,000Source | 500,000Source | — |
| Deconsolidation, Gain (Loss), AmountUSD | — | — | — | — | — | — | — | 0Source | 0Source | 79,000Source | 0Source | 0Source |
| Equity Securities, FV-NI, Gain (Loss)USD | — | — | 3,470,000Source | 5,666,000Source | 0Source | 4,640,000Source | 0Source | -7,023,000Source | 1,239,000Source | 5,228,000Source | — | — |
| Equity Securities, FV-NI, Realized Gain (Loss)USD | — | — | 2,975,000Source | 5,666,000Source | 0Source | 0Source | 0Source | 0Source | 1,239,000Source | 7,918,000Source | — | — |
| Equity Securities, FV-NI, Unrealized Gain (Loss)USD | — | — | 495,000Source | 0Source | 0Source | 4,640,000Source | 0Source | -7,023,000Source | 0Source | -2,690,000Source | — | — |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | — | 0Source | 660,000Source | 13,000Source | -406,000Source | -56,000Source |
| General and Administrative ExpenseUSD | — | — | 10,784,000Source | 14,608,000Source | 9,228,000Source | 8,448,000Source | 9,139,000Source | 10,580,000Source | 37,717,000Source | 87,115,000Source | 64,351,000Source | 54,553,000Source |
| GoodwillUSD | — | — | — | 3,736,000Source | — | — | — | — | — | 0Source | 3,736,000Source | 3,736,000Source |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | — | — | 0Source | 3,736,000Source | 0Source | — |
| Impairment of Intangible Assets (Excluding Goodwill)USD | — | — | — | — | — | — | — | — | — | — | 0Source | — |
| Impairment of Intangible Assets, Finite-livedUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Income (Loss) from Equity Method InvestmentsUSD | — | — | — | 0Source | — | — | — | — | 0Source | 0Source | -16,014,000Source | -16,282,000Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | -27,000Source | 138,000Source | 0Source | 120,000Source | 0Source | 442,000Source | 177,000Source | -601,000Source | -469,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -26,691,000Source | -40,158,000Source | -42,286,000Source | -26,874,000Source | -35,352,000Source | -48,279,000Source | -137,060,000Source | -165,839,000Source | -292,191,000Source | -236,806,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | — | — | 0Source | 0Source | — | 0Source | — | 0Source | 0Source | -28,000Source | -114,000Source | -307,000Source |
| Operating ExpensesUSD | — | — | 33,734,000Source | 51,432,000Source | 44,391,000Source | 36,058,000Source | 37,855,000Source | 45,623,000Source | 152,808,000Source | 258,619,000Source | 299,509,000Source | 227,287,000Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | — | 6,800,000Source | 6,900,000Source | 6,900,000Source | 7,000,000Source |
| Operating Lease, Impairment LossUSD | — | — | — | — | — | — | — | — | 3,000,000Source | 0Source | 4,953,000Source | — |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | 5,390,000Source | 0Source | 235,680,000Source | 257,922,000Source |
| Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-saleUSD | — | — | — | — | — | — | 60,000,000Source | 60,000,000Source | 250,000,000Source | 271,200,000Source | 505,307,000Source | 421,529,000Source |
| Proceeds from Noncontrolling InterestsUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | — | — | — | 8,000Source | 1,000,000Source | 2,200,000Source |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 0Source | 0Source | — | 0Source | — | 0Source | 0Source | 67,425,000Source | — | — |
| Operating Income (Loss)USD | — | — | -33,734,000Source | -51,432,000Source | -44,391,000Source | -36,058,000Source | -37,855,000Source | -45,623,000Source | -152,808,000Source | -191,194,000Source | -299,509,000Source | -227,287,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -26,691,000Source | -40,185,000Source | -42,148,000Source | -26,874,000Source | -35,232,000Source | -48,279,000Source | -136,618,000Source | -165,690,000Source | -292,906,000Source | -237,582,000Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | -27,000Source | 138,000Source | 0Source | 120,000Source | 0Source | 442,000Source | 177,000Source | -601,000Source | -469,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | — | — | 0Source | 0Source | — | 0Source | — | 0Source | 0Source | -28,000Source | -114,000Source | -307,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -26,691,000Source | -40,158,000Source | -42,286,000Source | -26,874,000Source | -35,352,000Source | -48,279,000Source | -137,060,000Source | -165,839,000Source | -292,191,000Source | -236,806,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.37Source | -0.56Source | -0.59Source | -0.37Source | -0.5Source | -0.67Source | -1.91Source | -2.33Source | -4.47Source | -4.48Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.37Source | -0.56Source | -0.59Source | -0.37Source | -0.5Source | -0.67Source | -1.91Source | -2.33Source | -4.47Source | -4.48Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 72,139,000Source | 71,111,000Source | 71,326,000Source | 71,992,000Source | 70,264,000Source | 71,678,000Source | 71,869,000Source | 71,080,000Source | 65,409,000Source | 52,857,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 72,139,000Source | 71,111,000Source | 71,326,000Source | 71,992,000Source | 70,264,000Source | 71,678,000Source | 71,869,000Source | 71,080,000Source | 65,409,000Source | 52,857,000Source |
| Additional Financial Items | ||||||||||||
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 391,000Source | 240,000Source | 290,000Source | 309,000Source |
| Equity Securities, FV-NI, Realized Gain (Loss)USD | — | — | 2,975,000Source | 5,666,000Source | 0Source | 0Source | 0Source | 0Source | 1,239,000Source | 7,918,000Source | — | — |
| General and Administrative ExpenseUSD | — | — | 10,784,000Source | 14,608,000Source | 9,228,000Source | 8,448,000Source | 9,139,000Source | 10,580,000Source | 37,717,000Source | 87,115,000Source | 64,351,000Source | 54,553,000Source |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | — | — | 0Source | 3,736,000Source | 0Source | — |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -136,986,000Source | -165,490,000Source | -293,284,000Source | -237,926,000Source |
| Income (Loss) from Equity Method InvestmentsUSD | — | — | — | 0Source | — | — | — | — | 0Source | 0Source | -16,014,000Source | -16,282,000Source |
| Operating ExpensesUSD | — | — | 33,734,000Source | 51,432,000Source | 44,391,000Source | 36,058,000Source | 37,855,000Source | 45,623,000Source | 152,808,000Source | 258,619,000Source | 299,509,000Source | 227,287,000Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | — | 6,800,000Source | 6,900,000Source | 6,900,000Source | 7,000,000Source |
| Research and Development ExpenseUSD | — | — | 22,950,000Source | 36,824,000Source | 35,163,000Source | 27,610,000Source | 28,716,000Source | 27,247,000Source | 107,295,000Source | 167,768,000Source | 189,590,000Source | 172,734,000Source |
| Restructuring and Related Cost, Incurred CostUSD | — | — | — | — | — | — | — | 6,990,000Source | 6,990,000Source | — | — | — |
Filing attachments
ex992-leeetalazenointnbc.htm · 8-K · 2026-04-17
EX-99.2 3 ex992-leeetalazenointnbc.htm EX-99.2 ex992-leeetalazenointnbc METHODS Analysis of pharmacogenomic and proteomic datasets • Comparison of Cyclin E1 protein levels in serous ovarian cancer (SOC) and basal‑like breast cancer was determined from TCGA pan‑cancer analysis.5 Although not all basal‑like breast cancers are TNBC, they demonstrate substantial molecular and histological overlap6 and are consequently enriched for TNBC. For simplicity, we refer to this population as ~TNBC • Bre…
Read attachment ↗ex991-zntlcorporateprese.htm · 8-K · 2026-04-09
EX-99.1 2 ex991-zntlcorporateprese.htm EX-99.1 ex991-zntlcorporateprese Corporate Presentation April 2026 Nasdaq: ZNTL 2 Zentalis Pharmaceuticals, Inc. (“we,” “us,” “our,” “Zentalis” or the “Company”) cautions that this presentation (including oral commentary that accompanies this presentation) contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements contained in this presentation that do not relate to matters of hi…
Read attachment ↗ex991-clopressrelease.htm · 8-K · 2025-08-26
EX-99.1 2 ex991-clopressrelease.htm EX-99.1 Document Exhibit 99.1 Zentalis Pharmaceuticals Appoints James B. Bucher, JD, as Chief Legal Officer and Corporate Secretary Seasoned life sciences legal executive brings extensive public company experience, including broad strategic and financial transaction expertise SAN DIEGO - August 26, 2025 - Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class …
Read attachment ↗